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Abstract
The genetically heterogeneous taxon Candida parapsilosis was
recently reclassiﬁed into three species: Candida parapsilosis,
Candida orthopsilosis and Candida metapsilosis. The prevalences of
these species among 141 bloodstream isolates tested in Brazil
were 88% for C. parapsilosis, 9% for C. orthopsilosis, and 3% for
C. metapsilosis. Except for three C. orthopsilosis isolates that were
considered resistant to 5-ﬂucytosine, all isolates representing
the different species of this complex were susceptible to poly-
enes, triazoles and caspofungin.
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Candida parapsilosis is one of the most frequent species caus-
ing candidaemia in hospitalized patients. In Europe, C. parapsi-
losis is the second or third most common agent, being
responsible for 15–23% of all candidaemic episodes [1,2],
and in the USA, C. parapsilosis is the third most common
agent in patients >12 years (12%) and the second most com-
mon in younger patients (34%) [3,4]. In Brazil and other
Latin American countries, C. parapsilosis accounts for 20–30%
of candidaemias, exhibiting similar prevalence rates among
adult and paediatric populations [5–7].
The genetically heterogeneous taxon C. parapsilosis was
reclassiﬁed into three species: C. parapsilosis, Candida orthopsi-
losis and Candida metapsilosis [8].
Recently, several authors have attempted to evaluate the
burden of superﬁcial and invasive fungal infections due to
C. orthopsilosis and C. metapsilosis [9,10]. Lockart et al. evalu-
ated 1929 presumed C. parapsilosis isolates from the world-
wide collection of the ARTEMIS Antifungal Surveillance
Program. The prevalence rate of C. parapsilosis complex
species varied by region, and the highest prevalence of C. ort-
hopsilosis was found in South America (10.9%). However,
considering that most strains tested in the ARTEMIS study
were obtained from different body sites and tissues, it is not
clear whether these ﬁndings may be extrapolated to the
epidemiology of candidaemia [10]. Van Asbeck et al. [7] also
found that prevalence rates of C. parapsilosis complex species
varied by geographical region, and that C. parapsilosis sensu
stricto was the most prevalent species in both superﬁcial and
invasive infections.
The most robust data regarding the epidemiology of hae-
matogenous infections caused by members of the C. parapsi-
losis complex were obtained by molecular identiﬁcation of 87
presumed C. parapsilosis isolates collected during a popula-
tion-based surveillance of candidaemia in Spain. C. orthopsilosis
and C. metapsilosis isolates were responsible for 5.7% and
6.8% of infections, respectively [9].
Despite all of these contributions to the ﬁeld, the epide-
miology of haematogenous infections caused by species of
the C. parapsilosis complex is still not completely under-
stood. This report provides data on the antifungal suscepti-
bility proﬁles and prevalence rates of C. orthopsilosis and
C. metapsilosis among 141 presumed C. parapsilosis blood-
stream isolates collected during a multicentre surveillance
study conducted in Brazil between 2003 and 2004. The
study was a prospective laboratory-based survey of candida-
emia, conducted in 11 general hospitals located in nine
cities of Brazil during a 24-month period. Details of the
patient characteristics are presented in the original publica-
tion [6]. Brieﬂy, the median age was 41 years (21% <1 year),
cancer was the most frequent underlying disease (27%), and
46% of patients were in an intensive-care unit. Each isolate
tested represents a different episode of candidaemia.
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Screening of C. parapsilosis complex isolates was based on
the evaluation of yeast micromorphology and biochemical
tests using the ID32 C System (bioMe´rieux, Marcy l’Etoile,
France).
For molecular identiﬁcation, DNA was extracted from sin-
gle colonies using the fast small-scale isolation procedure
described previously [11]. The internal transcribed spacer
sequence is a non-coding region of the conserved rRNA
genes. Therefore, it presents a high rate of polymorphism
and has been used as a tool for the identiﬁcation of fungal
species [12]. The internal transcribed spacer region was
ampliﬁed and sequenced using the C. parapsilosis-speciﬁc
primers CparapITSout F (5¢-CCGTCGTGCTGGGGATA-
GAG-3¢) and CparapITSout R (5¢-CATCGCACGGGATTCT-
CACC-3¢). Nucleotide sequences were analysed using the
Blastn program at the NCBI site (http://www.ncbi.nlm.nih.-
gov) for species identiﬁcation.
Antifungal susceptibility testing was performed using the
CLSI broth microdilution method [13]. The following antifun-
gal drugs were tested: amphotericin B, 5-ﬂucytosine, ﬂuco-
nazole, voriconazole, itraconazole and caspofungin. Although
endpoint reading for caspofungin is not mentioned in the
CLSI protocol, MIC endpoints were determined after 24 h,
on the basis of a prominent decrease in growth as compared
with that of the drug-free growth control, as suggested by
other authors [10]. Differences in antifungal susceptibility
patterns among species were evaluated using ANOVA.
After sequencing of amplicons from 141 isolates, 124
(88%) were identiﬁed as C. parapsilosis, 13 (9%) as C. orthopsi-
losis, and four (3%) as C. metapsilosis. This ﬁnding is consis-
tent with data previously published by Lockhart et al. [10]
after testing strains of the C. parapsilosis complex from Latin
America, and indicate that the prevalence of bloodstream
infections caused by C. orthopsilosis in that region (9%) is
probably higher than that in Europe (3.5–5.7%) and the USA
(5%) [9,10]. We also found that the prevalence of C. metapsi-
losis fungaemia in Brazil (3%) was lower than that docu-
mented in Spain (6.9%) [9].
Table 1 shows the results of antifungal susceptibility tests.
All isolates were equally susceptible to amphotericin B, vorico-
nazole, itraconazole and caspofungin. Despite the fact that
MIC50 and MIC90 values for C. metapsilosis isolates were
considerably higher than those obtained for C. parapsilosis
sensu stricto and C. orthopsilosis, no single isolate was consid-
ered to have Dose Dependent Susceptibility (DDS) and/or
resistance to azoles. It is of note that Van Asbeck et al. [14]
also found that C. metapsilosis strains were slightly less suscep-
tible to ﬂuconazole than were strains of the other species.
Consistent with data previously reported by Tavanti et al. [15],
the 5-ﬂucytosine MIC90 values obtained for our C. orthopsilosis
isolates were signiﬁcantly higher than those for the C. parapsilo-
sis and C. metapsilosis isolates (p <0.05). Finally, in contrast to
our data, Lockhart et al. [10] found that the MICs of echino-
candins for C. parapsilosis isolates were generally higher than
than those for C. orthopsilosis and C. metapsilosis isolates.
In conclusion, the data obtained here from a collection of
141 presumed C. parapsilosis bloodstream isolates show that
9% of them were C. orthopsilosis and that 3% were C. metapsi-
losis. Except for a few isolates of C. orthopsilosis which were
considered to be resistant to 5-ﬂucytosine and four
C. metapsilosis isolates for which slightly higher MICs of
ﬂuconazole were determined, most isolates were equally
susceptible to polyenes, voriconazole and caspofungin.
Although the isolates analysed here were obtained from the
largest epidemiological study of candidaemia ever reported in
Latin America, these data are not necessarily representative
of the entire region. Therefore, further studies with larger
number of isolates are needed to conﬁrm possible biological
TABLE 1. In vitro susceptibility of
the members of the Candida par-
apsilosis complex to six antifungal
agents
Drug Species
Range of
MIC (mg/L) MIC50 MIC90 Mean
Amphotericin B Candida parapsilosis (n = 124) 0.25–1 1.0 1.0 0.8
Candida orthopsilosis (n = 13) 0.25–1 0.5 1.0 0.62
Candida metapsilosis (n = 4) 0.25–1 0.5 1.0 0.69
Fluconazole C. parapsilosis (n = 124) 0.125–8 1.0 2.0 1.19
C. orthopsilosis (n = 13) 0.5–2.0 1.0 2.0 1.5
C. metapsilosis (n = 4) 2.0–4 4 4 3.5
5-Flucytosine C. parapsilosis (n = 124) 0.125–2.0 0.25 0.5 0.26
C. orthopsilosis (n = 13) 0.125 to >64 0.5 >64 11.47
C. metapsilosis (n = 4) 0.125–0.25 0.25 0.25 0.22
Itraconazole C. parapsilosis (n = 124) 0.03–0.5 0.03 0.06 0.04
C. orthopsilosis (n = 13) 0.03–0.125 0.06 0.125 0.07
C. metapsilosis (n = 4) 0.03–0.06 0.06 0.06 0.05
Caspofungin C. parapsilosis (n = 124) 0.5–2.0 1.0 1.0 1.08
C. orthopsilosis (n = 13) 0.5–2.0 1.0 1.0 0.88
C. metapsilosis (n = 4) 0.5–1 0.5 1.0 0.75
Voriconazole C. parapsilosis (n = 124) 0.03–0.125 0.03 0.03 0.05
C. orthopsilosis (n = 13) 0.03–0.06 0.03 0.06 0.04
C. metapsilosis (n = 4) 0.03–0.125 0.03 0.125 0.06
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differences, as well as to evaluate the clinical relevance of the
three species of the C. parapsilosis complex.
Transparency Declaration
This study was supported by FAPESP, Brazil (grant 2005/
50778-1). S. S. Gonc¸alves, C. S. Amorim and A. S. A. Melo
received MSc, PhD and postdoctoral fellowships, respec-
tively, from CAPES (Brazil). A. L. Colombo received a grant
from CNPq (Brazil) (304802/2007-7). M. Nucci received a
grant from CNPQ (Brazil) (301025/2008-8). The authors
have no conﬂicting interests to declare.
References
1. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors
of mortality in cases of Candida bloodstream infection: results from
population-based surveillance, Barcelona, Spain, from 2002 to 2003.
J Clin Microbiol 2005; 43: 1829–1835.
2. Tortorano AM, Biraghi E, Astolﬁ A et al. European Confederation of
Medical Mycology (ECMM) prospective survey of candidaemia: report
from one Italian region. J Hosp Infect 2002; 51: 297–304.
3. Trofa D, Ga´cser A, Nosanchuk JD. Candida parapsilosis, an emerging
fungal pathogen. Clin Microbiol Rev 2008; 21: 606–625.
4. Pappas PG, Rex JH, Lee J et al. A prospective observational study of
candidemia: epidemiology, therapy, and inﬂuences on mortality in
hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634–
643.
5. Brito LR, Guimaraes T, Nucci M et al. Clinical and microbiological
aspects of candidemia due to Candida parapsilosis in Brazilian tertiary
care hospitals. Med Mycol 2006; 44: 261–266.
6. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in
Brazil: a nationwide sentinel surveillance of candidemia in eleven
medical centers. J Clin Microbiol 2006; 44: 2816–2823.
7. Van Asbeck EC, Clemons KV, Markham AN, Stevens DA, The Can-
dida parapsilosis Global Epidemiology Group. Molecular epidemiology
of the global and temporal diversity of Candida parapsilosis. Scand J
Infect Dis 2008; 40: 827–834.
8. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida
orthopsilosis and Candida metapsilosis spp. nov. to replace Candida par-
apsilosis groups II and III. J Clin Microbiol 2005; 43: 284–292.
9. Gomez-Lopez A, Alastruey-Izquierdo A, Rodrigues D et al. Preva-
lence and susceptibility proﬁle of Candida metapsilosis and Candida ort-
hopsilosis: results from population-based surveillance of candidemia in
Spain. Antimicrob Agents Chemother 2008; 52: 1506–1509.
10. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Geographic distri-
bution and antifungal susceptibility of the newly described species
Candida orthopsilosis, in comparison to the closely related species
Candida parapsilosis. J Clin Microbiol 2008; 46: 2659–2664.
11. Melo AS, Padovan AC, Seraﬁm RC et al. The Candida albicans AAA
ATPase homologue of Saccharomyces cerevisiae Rix7p (YLL034c) is
essential for proper morphology, bioﬁlm formation and activity of
secreted aspartyl proteinases. Genet Mol Res 2006; 5: 664–687.
12. Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive candidia-
sis. J Microbiol 2005; 43: 65–84.
13. Clinical and Laboratory Standard Institute. Reference method for broth
dilution antifungal susceptibility testing of yeasts. Approved standard M27-
A2 272. CLSI: Wayne, PA, 2002.
14. Van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens D.
Signiﬁcant differences in drug susceptibility among species in the
Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62:
106–109.
15. Tavanti A, Hensgens LA, Ghelardi E, Campa M, Senesi S. Genotyping
of Candida orthopsilosis clinical isolates by ampliﬁcation fragment
length polymorphism reveals genetic diversity among independent
isolates and strain maintenance within patients. J Clin Microbiol 2007;
45: 1455–1462.
CMI Research Note 887
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 885–887
